A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06667076
Trial Phases:	Phase II	Protocol IDs:	61186372NSC2012 (primary) NCI-2025-00167 61186372NSC2012
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Janssen Research & Development, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06667076

Summary

The primary purpose of the study is to assess how well amivantamab subcutaneous (SC)
administration in combination with lazertinib or in combination with chemotherapy works
(antitumor activity) in participants with epidermal growth factor receptor mutated
(EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung
cancer).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.